Literature DB >> 11011015

Ovarian steroids influence the activity of neuroendocrine dopaminergic neurons.

J E DeMaria1, J D Livingstone, M E Freeman.   

Abstract

The secretion of prolactin (PRL) from the anterior lobe (AL) of the pituitary gland is tonically inhibited by dopamine (DA) of hypothalamic origin. While ovarian steroids play a role in the regulation of the secretion of PRL, their effect on all three populations of hypothalamic neuroendocrine dopaminergic neurons is not fully understood. In this study we describe the effects of ovarian steroids on regulation of the release of DA from tuberoinfundibular dopaminergic (TIDA), tuberohypophyseal dopaminergic (THDA) and periventricular-hypophyseal dopaminergic (PHDA) neurons. Adult female rats were bilaterally ovariectomized (OVX) and, 10 days following ovariectomy (day 0), injected with corn oil (vehicle), estrogen, or estrogen plus progesterone (day 1). Animals were sacrificed every 2 h from 09.00 to 21.00 h by rapid decapitation. Trunk blood was collected and the concentration of PRL in serum was determined by radioimmunoassay. The median eminence (ME) and the AL, intermediate (IL) and neural (NL) lobes of the pituitary gland were dissected and the concentration of DA and DOPAC in each was measured by HPLC-EC. OVX rats presented small but significant increases in the secretion of PRL at 15.00 and 17.00 h. Replacement of estrogen or estrogen plus progesterone increased the basal concentration of PRL. Moreover, injection of estrogen only, or estrogen plus progesterone increased the concentration of PRL in serum at 15.00 h through 19.00 h, respectively, followed by a decrease to baseline thereafter. The turnover of DA in the ME and NL of OVX rats increased at 13.00 and returned to low levels. Turnover of DA in the IL of OVX rats increased in the morning by 11.00 h and remained elevated before decreasing by 17.00 h. The turnover of DA in the ME, IL and NL of OVX rats increased by 19.00 h. Injection of estrogen advanced the increase of TIDA activity by 2 h in the ME compared to OVX rats. Moreover, administration of estrogen suppressed the activity of THDA and PHDA neurons in the afternoon compared to OVX rats. In estrogen plus progesterone-treated rats, the activity of hypothalamic neuroendocrine dopaminergic neurons terminating in the ME, IL, and NL was inhibited prior to the increase in the secretion of PRL. The concentration of DA in the AL diminished prior to the estrogen-induced increase of PRL. Administration of progesterone, in concert with estrogen, delayed the increase of PRL in serum and the decrease of DA in the AL, compared to estrogen-treated rats, by 4 h. These data suggest a major role for ovarian steroids in controlling increases in the secretion of PRL by not only stimulating PRL release from lactotrophs, but also by inhibiting the activity of all three populations of hypothalamic neuroendocrine DAergic neurons.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11011015     DOI: 10.1016/s0006-8993(00)02763-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  21 in total

1.  Differential hypothalamic secretion of neurocrines in male common marmosets: parental experience effects?

Authors:  M J Woller; M E Sosa; Y Chiang; S L Prudom; P Keelty; J E Moore; T E Ziegler
Journal:  J Neuroendocrinol       Date:  2012-03       Impact factor: 3.627

2.  Differential sensitivity of specific neuronal populations of the rat hypothalamus to prolactin action.

Authors:  Tony J Sapsford; Ilona C Kokay; Lovisa Ostberg; Robert S Bridges; David R Grattan
Journal:  J Comp Neurol       Date:  2012-04-01       Impact factor: 3.215

3.  Anatomical and functional characterization of clock gene expression in neuroendocrine dopaminergic neurons.

Authors:  Michael T Sellix; Marcel Egli; Maristela O Poletini; De'Nise T McKee; Matthew D Bosworth; Cheryl A Fitch; Marc E Freeman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-12-22       Impact factor: 3.619

4.  Oxytocin action at the lactotroph is required for prolactin surges in cervically stimulated ovariectomized rats.

Authors:  De'Nise T McKee; Maristela O Poletini; Richard Bertram; Marc E Freeman
Journal:  Endocrinology       Date:  2007-07-05       Impact factor: 4.736

5.  Estrogen inhibits tuberoinfundibular dopaminergic neurons but does not cause irreversible damage.

Authors:  Gustavo R Morel; Rubén W Carón; Gloria M Cónsole; Marta Soaje; Yolanda E Sosa; Silvia S Rodríguez; Graciela A Jahn; Rodolfo G Goya
Journal:  Brain Res Bull       Date:  2009-09-08       Impact factor: 4.077

6.  Response to nicotine following overnight smoking abstinence during short-term progesterone treatment in women.

Authors:  Sharon Allen; Ashley Petersen; Katherine Harrison; Nicole Tosun; Jacquelyn Cameron
Journal:  Exp Clin Psychopharmacol       Date:  2019-08-29       Impact factor: 3.157

Review 7.  The parental brain and behavior: A target for endocrine disruption.

Authors:  Matthieu Keller; Laura N Vandenberg; Thierry D Charlier
Journal:  Front Neuroendocrinol       Date:  2019-05-18       Impact factor: 8.606

8.  The effect of anandamide on prolactin secretion is modulated by estrogen.

Authors:  Camila Scorticati; Claudia Mohn; Andrea De Laurentiis; Paula Vissio; Javier Fernández Solari; Adriana Seilicovich; Samuel M McCann; Valeria Rettori
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-10       Impact factor: 11.205

9.  The characteristic change in the distribution of S-100 immunoreactive folliculostellate cells in rat anterior pituitary upon long-term estrogen treatment is prevented by concomitant progesterone treatment.

Authors:  Andrea Heinzlmann; Katalin Köves
Journal:  Endocrine       Date:  2008-06       Impact factor: 3.633

10.  Estradiol-induced synaptic remodeling of tyrosine hydroxylase immunopositive neurons in the rat arcuate nucleus.

Authors:  Eszter Csakvari; Anita Kurunczi; Zsofia Hoyk; Andrea Gyenes; Frederick Naftolin; Arpad Parducz
Journal:  Endocrinology       Date:  2008-04-17       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.